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Introduction. 11C-choline-PET/CT is a promising technique for detection/restaging of patients with biochemical failure (BF) after
curative therapy for prostate cancer (PCA). The aim of this paper was to evaluate the PSA response in patients with BF after
radical prostatectomy (RP) who underwent secondary lymphadenectomy (LAD) due to 11C-choline-PET/CT ﬁndings. Material
and Methods. Eight patients with BF and positive lymph nodes in 11C-choline-PET/CT after RP were retrospectively included in
the study. Extended LAD until the common iliac arteries was performed in all patients. Results. Six of 8 patients had histologically
proven lymph node metastases. Four patients showed an initial PSA reduction after LAD, and in 4 patients the PSA increased. Two
of the latter had no histological lymph node metastases. Conclusions. Because 50% of our patients showed an initial PSA response,
our data suggest that positive 11C-choline-PET/CT after RP and BF could help to select patients that could beneﬁt from secondary
LAD.
1.Introduction
The incidence of recurrent disease after the initial curative
treatment of local PCA ranges from 30 to 50% after RP
[1, 2] and up to 80% after extracorporal radiotherapy [3].
An increasing PSA is the most certain indicator for relapse,
but it does not always help in diﬀerentiating between local
recurrence and systemic spread of the disease [4]. PSA
kinetics and imaging techniques play an important role in
the diagnostic of PCA recurrence after primary treatment.
Positron emission tomography/computed tomography
with choline tracer (11C-choline-PET/CT) has emerged as a
promising technique for restaging patients with BF. Tumor
cells are known to have a higher turnover of essential
cell membrane components, such as phosphatidylcholine,
[5]. After uptake by tumor cells, radioactive choline is
phosphorylated in high concentration and built into the cell
membrane and can be recognized by PET [6]. PCA or its
metastases can be detected by 11C-choline-PET/CT [7]. The
aim of this paper was to retrospectively evaluate the PSA
response after secondary LAD in patients with a BF and
positive lymph nodes in 11C-choline-PET/CT after RP.
2.MaterialandMethods
Eight consecutive patients between 2009 and 2011 with
BF and positive lymph nodes in 11C-choline-PET/CT were
retrospectively included in the study. Because of a PCA,
5 patients had initially undergone a retropubic RP with
a pelvic LAD and 3 a perineal RP without LAD. Local
recurrencewasexcludedbytransrectalultrasoundanddigital
rectal examination. All patients were informed of the pure
diagnostic value and the risk of a surgical intervention. 11C-
choline-PET/CT imaging results were analysed by a nuclear
medicine specialist in all 8 cases. The patients subsequently
underwent a secondary open extended LAD, performed by2 Advances in Urology
Table 1
Patient Age Primary treatment Initial tumor stage Gleason score
Hormonal therapy
after primary
treatment
Radiotherapy
after primary
treatment
1 57 RP pT3aN0MxR1 9 (4 + 5) ++
2 54 RP pT2cN0MxR0 8 (4 + 4) ++
3 62 RPP pT2bNxMxR1 6 (3 + 3) −−
4 65 RP pT3bN0MxR0 7 (4 + 3) − +
5 59 RP pT2aN0MxR0 7 (4 + 3) − +
6 68 RPP pT3aN0MxR1 6 (3 + 3) ++
7 68 RPP pT3bN0MxR1 9 (5 + 4) − +
8 75 RP pT4N1MxR1 7 (4 + 3) − +
RP: radical prostatectomy; RPP: Radical perineal prostatectomy.
Table 2
Patient PSA 1(ng/mL) PSA 2(ng/mL) PSA 3(ng/mL) PSA 4(ng/mL) Lymph nodes
resected n
Lymph nodes
positive n
1 6.14 0 1.38 1.6 24 3
2 5.54 0.64 1.57 0.1 31
3 8.56 0 0.17 0.2 17 0
4 8.32 0 1.66 1.74 51
5 7.62 0 2.92 1.34 20 1
6 6.94 0.53 2.93 4.1 11 0
7 5.23 0 2.43 0.66 12 1
8 9.81 0.13 1.5 0.11 11
PSA 1: initial PSA at time of cancer diagnosis; PSA 2: PSA after primary treatment; PSA 3: PSA at time of PET imaging; PSA 4: PSA after lymphadenectomy.
2 of our experienced department surgeons. The extended
LAD consisted of the dissection of lymph nodes from the
obturator fossa, the internal and external iliac artery, the
paravesicallymphnodes,andthecommoniliacartery.Inone
patient, only the 11C-choline-PET/CT-positive lymph node
around the external iliac artery was resected. Three to ﬁve
weeks after the LAD, the PSA value was determined and then
determined again at 3-month intervals.
3. Results
Patient characteristics are summarized in Tables 1 and 2.
T h em e d i a nP S Av a l u ea tt h et i m eo f11C-choline-PET/CT
was 1.62ng/mL (IQR 1.47ng/mL–2.56ng/mL). Deﬁnitive
histological lymph node metastases could be found in 6
of 8 patients with positive 11C-choline-PET/CT. In 2 of
the 6 patients with histological lymph node metastases,
the localization was not concordant with the 11C-choline-
PET/CT ﬁndings. Regarding PSA response after LAD, 4
patients showed a PSA increase: two of them showed
no sign of histological lymph node metastases, and the
other two had an increase of the PSA value, despite the
resection of the positive nodes. Three of them underwent
androgen deprivation therapy (ADT), and one patient has
been under observation with a stable PSA (0.21ng/mL) after
LAD for the last 29 months. Out of the 4 patients with
decreasing PSA, one patient had an undetectable PSA after
29 months of followup. A second patient showed a decrease
in PSA from 2.43ng/mL to 0.66ng/mL and remained stable
after 34 months of followup. After a period of 5 months
maintaining initial PSA response, the third patient showed
disease progression. He subsequently underwent an ADT,
and 31 months later he became castration resistant. He
then received chemotherapy with docetaxel. At 4 months of
followup, the fourth patient has not yet shown any increase
in PSA value.
4. Discussion
WhenBFoccursafteraradical treatmentforPCA,being able
to diﬀerentiate between local recurrence and distant metas-
tases plays a crucial role in choosing the appropriate course
of treatment. The functional imaging modality PET/CT has
been proven to be useful for restaging patients with a PSA
value which increases after RP. However, diﬀering ﬁgures can
be found in the literature with regard to the sensitivity and
speciﬁcity of this approach.
De Jong et al. analysethe role of the 11C-choline-PET/CT
for preoperative staging in 67 patients with histologically
provenPCA.Thisworkgaveasensitivityof80%,aspeciﬁcity
of 96%, and an accuracy of 93% for the detection of lymph
node metastases using 11C-choline-PET/CT. They conclude
that this tracer has a higher sensitivity than standard CT and
magnetic resonance imaging (MRI) [8].Advances in Urology 3
In patients with BF after RP, Scattoni et al. reported a
lower sensitivity 64% and a speciﬁcity of 90% for the 11C-
choline-PET/CT for the detection of lymph node metastases
[9].
The sensitivity of choline-PET/CT in patients with BF
after radical treatment for PC could range between 38 and
98% as was recently reported by Picchio et al. in their review
article. Such variability is to be attributed to diﬀerences
among patient cohorts [10]. The type of tumor and primary
treatment, extension of the LAD, and particularly the PSA
value at the time of choline-PET/CT could inﬂuence the
sensitivity and speciﬁcity of this imaging technique. Some
authors have stated that no positive lymph nodes could be
detected using 11C-choline-PET/CT in patients with BF and
PSA level <5ng/mL [11], but others have shown positive
PET/CT ﬁndings in patients with PSA values <5ng/mL,
albeit with a sensitivity reduction [12], and indeed this is in
concordant with our experience. For example, Picchio et al.
concluded that the routine use of choline-PET/CT cannot be
recommended for PSA values <1ng/mL[10]. Castellucci et
al. evaluated the role of 11C-choline-PET/CT in the restaging
of 102 patients after RP with only a slight PSA increase
<1.5ng/mL during followup. 11C-choline-PET/CT showed
positive ﬁndings in only 28% of the cases: local relapse in
7 patients, bone metastases in 13 patients, and lymph node
metastases in 9 patients. PSA doubling time and initial node
status were found to be signiﬁcant and independent factors
in a multivariate analysis for positive 11C-choline-PET/CT.
PSA doubling time in patients with positive PET ﬁndings
was 4.3 months and in PET-negative patients 13.3 months
(P = 0.0001). They concluded that the optimal threshold for
PSA doubling time was 7.2 months, providing 11C-choline-
PET/CT 93% sensitivity and 74% speciﬁcity [13].
In our cohort, 2 patients with BF showed no signs of
lymph node metastases in the ﬁnal histological analysis but
instead exhibited inﬂammatory altered tissue, and, in 2 fur-
ther patients, no positive nodes where found were these were
indicatedby 11C-choline-PET/CTgivingapositivepredictive
value (PPV) of 50%. Schilling et al. found a PPV of 70% in a
retrospective work similar to ours [14]. Inﬂammatory node
disease and small bowel activity (adherence and hernias)
seem to imitate positive lymph nodes. This is a known
phenomenon and can be explained by the high proliferation
activity of intestinal mucosa [8]. Our study showed a PSA
reduction in 4 patients (50%), and, in 3 cases (37.5%), this
response persisted at 29, 34, and 4 months of followup in the
respective patients.
Our results agree with the ﬁndings of Winter et al. In
theirstudy, 3of8patients withsingle lymphnode metastases
reached a complete PSA remission without adjuvant therapy.
Theyconcludedthataselectedpatientgroupseemstobeneﬁt
from secondary LAD [15]. Weckermann et al. also showed
that especially low-risk patients proﬁt from the resection of
the lymph node metastases and that 60% of patients with
resected metastases were free of relapse without adjuvant
therapy after 18 months [16]. It should also be determined
whether patients that beneﬁt from a secondary LAD had
an optimal LAD at the time of primary treatment. In fact,
data in the literature aﬃrm that microscopic metastatic
pelvic node disease could be cured by means of surgery
and extended LAD. Bader et al., for example, found that
38.5% of the patients with one positive lymph node, 10%
with two, and 14% with multiple lymph node metastases
remained relapse-free for 45 months in a cohort of post-RP
and extended LAD patients [17].
5. Conclusions
Extended LAD should be carefully performed at the time of
the ﬁrst treatment.
In case of BF without local recurrence, 11C-choline-
PET/CT could be performed if the PSA value is >1ng/mL,
to select patients that may beneﬁt from a secondary LAD.
Since positive lymph nodes have been found outside
the regions indicated by 11C-choline-PET/CT, a complete
extended secondary LAD should always be performed.
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